{"entity":{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","aka":[],"tldr":"Principal investigator of SPOTLIGHT and DESTINY-Gastric01, two trials that created new drug classes for stomach cancer.","summary":"Kohei Shitara is Chief of the Department of Gastrointestinal Oncology at the National Cancer Center Hospital East in Japan. He was principal investigator of SPOTLIGHT, which tested the Claudin 18.2 antibody zolbetuximab with mFOLFOX6, and of DESTINY-Gastric01, which tested trastuzumab deruxtecan in previously treated HER2-positive gastric cancer, two trials that created new drug classes for stomach cancer. He also led KEYNOTE-062 and sits on the steering committees of most current gastric cancer phase 3 trials, including GLOW and DESTINY-Gastric04. His publications include the DESTINY-Gastric01 and SPOTLIGHT reports, and his interests span HER2, Claudin 18.2, immunotherapy and antibody-drug conjugates.","asOf":"2026-09-08","links":[{"label":"National Cancer Center Hospital East","url":"https://www.ncc.go.jp/en/ncce/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shitara%20K%5BAuthor%5D%20gastric%20cancer"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":["her2","cldn18-2"],"drugs":["zolbetuximab","trastuzumab-deruxtecan"],"companies":[],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":["spotlight-glow","destiny-gastric04","toga"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Department of Gastrointestinal Oncology, National Cancer Center Hospital East","institutionId":"ncc-japan","specialisms":["Gastric cancer","HER2 and Claudin 18.2","Immunotherapy","Antibody-drug conjugates"],"profiles":[{"label":"National Cancer Center Hospital East","url":"https://www.ncc.go.jp/en/ncce/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shitara%20K%5BAuthor%5D%20gastric%20cancer"}],"papers":[{"title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer (DESTINY-Gastric01)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2004413"},{"title":"Zolbetuximab plus mFOLFOX6 in CLDN18.2-positive gastric or GEJ adenocarcinoma (SPOTLIGHT)","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)00620-7"},{"title":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","journal":"The Lancet","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate+649+nivolumab+chemotherapy+gastric+Janjigian+Lancet+2021"},{"title":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPOTLIGHT+zolbetuximab+mFOLFOX6+Shitara+Lancet"},{"title":"KEYNOTE-062: pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy in PD-L1-positive advanced gastric cancer","journal":"JAMA Oncology","year":2020,"url":"https://doi.org/10.1001/jamaoncol.2020.3370","doi":"10.1001/jamaoncol.2020.3370"}]},"route":"/people/shitara-kohei/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"},{"id":"zolbetuximab","kind":"drug","name":"Zolbetuximab","route":"/drugs/zolbetuximab/"}],"institution":[{"id":"ncc-japan","kind":"institution","name":"National Cancer Center Hospital","route":"/institutions/ncc-japan/"},{"id":"ncc-hospital-east","kind":"institution","name":"National Cancer Center Hospital East","route":"/institutions/ncc-hospital-east/"}],"trial":[{"id":"destiny-gastric01","kind":"trial","name":"DESTINY-Gastric01","route":"/trials/destiny-gastric01/"},{"id":"destiny-gastric04","kind":"trial","name":"DESTINY-Gastric04","route":"/trials/destiny-gastric04/"},{"id":"keynote-062","kind":"trial","name":"KEYNOTE-062","route":"/trials/keynote-062/"},{"id":"spotlight-glow","kind":"trial","name":"SPOTLIGHT & GLOW","route":"/trials/spotlight-glow/"},{"id":"toga","kind":"trial","name":"ToGA","route":"/trials/toga/"}],"paper":[{"id":"paper-checkmate-649-lancet-2021","kind":"paper","name":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","route":"/key-papers/paper-checkmate-649-lancet-2021/"},{"id":"paper-spotlight-lancet-2023","kind":"paper","name":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","route":"/key-papers/paper-spotlight-lancet-2023/"}]}}